26 search results for: asthma
Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation
Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.
ADVENT On Air | The Road Ahead: Achieving Remission for Patients With Asthma
Join Professors Klaus Rabe and Ian Pavord as they discuss the importance of on-treatment clinical remission as a goal in asthma management.
Corticosteroids in Asthma Management
This infographic illustrates the ongoing burden associated with maintenance oral corticosteroid (OCS) use and high-dose inhaled corticosteroids (ICS) in asthma, including the clinical impact of corticosteroid exposure, supporting evidence, and the importance of considering corticosteroid burden in asthma management.
ERS 2025 Enduring Video: Type 2 Severe Asthma “Unplugged”: Reducing Mucus to Improve Long- Term Patient Outcomes
Join Drs. Njira Lugogo, Simon Couillard, and Mario Castro for a session exploring the link between pathogenic mucus and impaired lung function in patients with moderate-to-severe asthma and the potential for disease modification with targeted therapy.
ADVENT at ATS 2026
At ATS 2026, the Sanofi & Regeneron ADVENT Booth #1301 brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.
ADVENT at ATS 2026
At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.
ADVENT at ERS 2026
Join Sanofi and Regeneron for four educational symposia on asthma, COPD, and the unified airway.
EAACI 2024 | On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control
Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.
ADVENT at CHEST 2026
At CHEST 2026, the Sanofi & Regeneron ADVENT Booth #833 brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.
Type 2 Asthma Learning Hub
Type 2 asthma is a common phenotype of asthma, characterized by key cytokines IL-4, IL-13, and IL-5, as well as elevated type 2 inflammatory biomarkers as FeNO, and eosinophils, or the need for maintenance OCS. Type 2 inflammation is evident in up to 88% of patients with severe asthma, representing a substantial portion of the disease burden associated with asthma. Explore the resources below better understand the role of type 2 inflammation in asthma.
ADVENT at ERS 2024
The ADVENT program will present four symposia sharing the latest science in asthma and COPD at the 2024 European Respiratory Society (ERS) Congress. Visit Booth #A4.02 to learn more about ADVENT.
Giselle Mosnaim, MD, MS, FAAAAI, FACAAI
Giselle Mosnaim is a board-certified allergist and immunologist at Endeavor Health and Clinical Assistant Professor at the University of Chicago Pritzker School of Medicine. An internationally recognized expert in asthma and allergic diseases, her clinical and research interests focus on severe and uncontrolled asthma, digital health, and improving patient outcomes through innovative, evidence-based care.
